http://medconferencestoday.com

Breaking Medical Conference News...

Namibia's Education Ministry Launches HIV/AIDS Booster Packs For Teachers, Staff

Namibia's Ministry of Education has made immune system booster packs part of its efforts to mitigate the effects of HIV/AIDS on the education sector in the country, the Namibian/AllAfrica.com reports.

The Henry Ford Production System LEAN Training Program

The Henry Ford Production System LEAN training program takes place March 11-12, 2010 at Henry Ford Health System in Detroit...

APhA Releases Student, Compounding, And Technician Books At End Of 2008

At the end of 2008, the American Pharmacists Association (APhA) published new editions of books for students entering their first professional year of study, pharmacists who compound and pharmacy technicians. Pharmacy: An Introduction to the Profession, 2nd edition (ISBN 978-1-58212-127-7; softbound; 211 pages; $29.95 [$27 for APhA members]), by L. Michael Posey, presents a concise, straightforward analysis of the top pharmacy issues and forces shaping the profession.

Anestvice Pressure Controller (APC) – device for maintaining of precisely set pressure in the cuff of Laryngeal Mask (LM) and Endotracheal Tube (ETT) during the surgery

Anestvice ( www.anestvice.com )Pressure Controller (APC) – device for maintaining of precisely set pressure in the cuff of Laryngeal Mask (LM) and Endotracheal Tube (ETT) during the surgery. During the surgery pressure in the cuff may fluctuate, thereby endangering the patient. Currently ...
(613) 686-5745 Cerepotec Pharmalef

Prevention Of Fatigue-Related Errors Requires Revised Hours And Workloads For Medical Residents

A new report from the Institute of Medicine proposes revisions to medical residents' duty hours and workloads to decrease the chances of fatigue-related medical errors and to enhance the learning environment for these doctors in training.

Launch Of New Interactive Renal Anaemia Resource For Physicians

EPG Health Media, developers of e-communication and clinical information solutions for the health sector, announced the launch of a new interactive Renal Anaemia Knowledge Centre within the web-based physician resource www.epgonline.org.

Annals Of Family Medicine September/October 2008

Cuts in Funding for Physician Training May Mean Fewer Physicians to Staff Community Health Centers Federal efforts to improve access to health care for underserved populations by expanding community health center capacity may be futile without continued federal support of Title VII primary care training grants.

The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity.

The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity. In addition to on-site responsibilities each CRA is responsible for site management documentation and follow-up activities ...
(613) 686-5745 Cerepotec Pharmalef

Diabetes UK To Lead National Care Planning Training

NHS Diabetes has contracted Diabetes UK to develop and deliver a model care planning training package. The package will be developed using the experience and expertise from the Year of Care - a national programme to improve the way in which diabetes care is provided - which has successfully identified what is needed to embed care planning as part of routine care.

Research Community's First 'Postercast' Capability Launched By 'SciVee' Science Site

SciVee, a Web 2.0 resource dedicated to the dissemination of scientific research and science-specific research networking, is adding an innovative new video feature called a "Postercast" that enables students and professional researchers alike to upload their poster and related video to create a synchronized presentation on the SciVee website.

Stricter Resident Duty Hour Regulations To Prevent Medical Errors Recommended By Institute Of Medicine

At the request of the House Committee on Energy and Commerce as part of an investigation into preventable medical errors, the Institute of Medicine (IOM) has issued a report recommending further restrictions regarding duty hours for resident physicians and other actions to reduce resident fatigue and ensure patient safety, according to an article published in the January issue ...

ClinQua Inc. : The overall cost of clinical trials depends on an array of factors

In a progressive global market of supply and demand, it remains unthinkable to engage in practices that are ambitiously over-priced when there are endless opportunities to utilize more cost-efficient methods which would yield the same results. As per Mr. David Mills former ClinQua Clinical ...
(613) 686-5745 Cerepotec Pharmalef

Patients At UCSD Hospital Three Times More Likely To Survive Cardiac Arrest With New Advanced Resuscitation Training Program

ZOLL Medical Corporation (NasdaqGS: ZOLL) announced that in a "Best of the Best" presentation at the American Heart Association Resuscitation Science Symposium in Orlando Florida, Daniel P. Davis, M.D., presented research from the University of California Resuscitation Research Center that shows a major improvement in patient outcome after cardiac arrest. Dr...

Train More GPs To Arrest Ageing Trend, Says Australian Medical Association

AMA President, Dr Rosanna Capolingua, today said it was extraordinary that even though one-third of Australian general practitioners are approaching retirement, the Government's GP training program this year turned away more than 100 would-be GPs. The Australian Institute of Health and Welfare (AIHW) reported today that 34 per cent of GPs were aged 55 years or over, and the proportion of younger GPs fell over the last decade.

Patients' Safety Not Compromised By Cut To Junior Doctors' Hours In UK

Research led by a team at the University of Warwick's Warwick Medical School has found that reducing the hours of junior doctors does not compromise patients' safety and could even dramatically cut mistakes on wards but, there are some concerns about reduced educational opportunities for junior doctors which it affords.

Clinical Trials Do Not Need To Be Expensive!

Many CRO Directors will argue that the foreseeable burden of clinical investigation is cost and the weight of that burden falls onto clients. The clinical climate has seen extraordinary escalation in federal regulations to make sure that the integrity of the products that are ...
(613) 686-5745 Cerepotec Pharmalef

Today's Opinions And Editorials

Now Is The Time For Latinas To Speak Up The Houston Chronicle Sometimes, if constituents lead, the leaders will follow. And that's why, at this moment, the voices of Latinas in Texas need to be at the forefront of this debate (Jessica Gonzalez-Rojas, 1/4)...

Exam Performance Of Ethnic Minority Medical Students Could Be Affected By 'Stereotype Threat'

The underperformance in examinations of UK medical students from ethnic minorities could be partly down to a psychological phenomenon called 'stereotype threat', according to new UCL research published in the British Medical Journal. Medical students from ethnic minority backgrounds make up approximately 30 per cent of the UK medical student population, but significantly underperform in assessments compared to their white counterparts.

Sofja Kovalevskaja Award For Dr. Jan-Erik Siemens - Investigating How Mammals Maintain Constant Body Temperature

The biochemist and neurobiologist Dr. Jan-Erik Siemens is one of eight junior researchers to receive this year's Sofja Kovalevskaja Award of the Alexander von Humboldt Foundation (AvH). The award stipend will enable the researcher to return to Germany next year after four years as postdoctoral fellow at the University of California, San Francisco, USA, in order to establish a research group at the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch.

Anestvice Pressure Controller (APC), is build to maintain the pre-set constant pressure in the cuff throughout the surgery despite of the factors influencing and/or altering this parameter.

Anestvice (www.anestvice.com ) Pressure Controller (APC) is designed for massive use for improvement of patient safety during all kinds of surgical procedures with the use of Laryngeal Mask (LM) and Endotracheal Tube (ETT) . Use of this device doesn’t require any specific knowledge or ...
(613) 686-5745 Cerepotec Pharmalef

Nursing Students Twice As Likely To Smoke As The General Population

Public health experts are calling for urgent steps to reduce the number of healthcare professionals who smoke, after a survey of more than 800 new nursing students found that more than half were current or former smokers. The Italian study, published in the January issue of the Journal of Advanced Nursing, surveyed 812 students who were just starting their University course...

Stanford Adopts New Approach To Continuing Medical Education To Prevent Industry Influence

Stanford University School of Medicine has developed a new, industry-funded model for the continuing education of physicians that aims to improve patient care while ensuring that corporate donors do not exert influence over the curriculum...

Plenary Speakers For ASMCUE 2010 Announced By American Society For Microbiology

The 17th American Society for Microbiology Conference for Undergraduate Educators (ASMCUE) will be held May 20 - 23, 2010, at the Town & Country Resort and Convention Center in San Diego, Calif. This interactive, four-day conference features outstanding plenary speakers and concurrent sessions where attendees learn and share the latest information in microbiology and biology education research...

The World Is Getting Better!

According to Bruce Kriger, CEO of Kriger Research Group International www.kriger.com, leading training institution and clinical research organization, the world is getting better, no matter what critics say. Today’s life expectancy is the highest in human history. In Western countries, we ...
(613) 686-5745 Cerepotec Pharmalef

Editorials, Opinion Piece Address Recent IOM Recommendations On Work Schedules For Medical Residents

Two newspapers recently published two editorials and an opinion piece about recent recommendations by an Institute of Medicine committee that medical residents who work a 30-hour shift should have a five-hour, uninterrupted break to sleep after they have worked 16 hours. Summaries appear below.

Trust Helps Pioneer Stroke Care Course, East Sussex, England

East Sussex Hospitals NHS Trust has become one of only four medical centres outside the USA to pilot an innovative advanced stroke care course for emergency medical professionals. The new educational programme was held at Eastbourne DGH last week and run by the South East Coast Ambulance Service NHS Trust (SECAmb) in collaboration with East Sussex Hospitals NHS Trust stroke teams.

Innovative Rural Student Named Medical Student Of The Year 2009

A passion for promoting the benefits of rural practice to other health students has seen rural NSW medical student, Shannon Nott, receive the Westpac RDAA Medical Student of the Year Award for 2009.

The Cerebroprotective Properties of Cereprotex (2,4,6,8-tetramethyl-2,4,6,8-tetraazabicyclo[3.3.0]-octane-3,7-dione) after traumatic and hypoxic brain injury

The cerebroprotective effect of Cereprotex (Patent pending – Cereprotec Inc. www.cereprotec.com ) (2,4,6,8-tetramethyl-2,4,6,8-tetraazabicyclo[3.3.0]-octane-3,7-dione) , previously known as (CombiCNS1), was assessed in a model of closed head injury in mice. This type of trauma produces ...
(613) 686-5745 Cerepotec Pharmalef

Spellex Releases World's First Multi-function Handheld Medical Spelling Wizard

Spellex announces the release of Spellex PocketMedtm, a handheld spell checking wizard for the healthcare industry. The new handheld device contains more than 300,000 medical, pharmaceutical, and English words plus a host of other useful functions for daily activities.

Researchers At Boston University School Of Medicine Incorporate Multisite Geriatric Clerkship

As the population ages, it is imperative that medical students are prepared to treat older adults, regardless of their specialty. Researchers at Boston University School of Medicine (BUSM) report that an interdisciplinary multisite fourth-year geriatrics clerkship, has successfully met all the ambulatory core geriatric competencies as outlined by the Association of American Medical Colleges (AAMC) working group.

HESA Performance Indicators Show That 1994 Group Universities Are 'elite But Not Elitist'

1994 Group universities are continuing to widen access to higher education, attracting over 4/5 of their students from state schools for a third consecutive year, as highlighted by statistics published by the Higher Education Statistics Agency (HESA.

Anestvice Inc. Phase II Clinical Trials for PC-LM Device have been successfully completed.

The research was conducted on 24 patients ranging in age from 13 to 74 years (the average age was 46.6 ±5.4), who underwent surgery in the urology clinic of the Rostov State Medical University. It was sponsored by Anestvice Inc. www.anestvice.com Baltimore based research and development ...
(613) 686-5745 Cerepotec Pharmalef

Educating Chief Residents About Addiction At Boston Medical Center

Researchers from Boston Medical Center (BMC) have found that education on addiction is inadequate during medical training, resulting in suboptimal medical care for those at risk. However, the research also found that a Chief Resident Immersion Training (CRIT) program in addiction medicine is an effective "train the trainers" model for dissemination of addiction knowledge and skills to generalist physician trainees. These findings appear in the Journal of General Internal Medicine.

Shortage Of Family Physicians Troubles States, ERs

"This spring, 385 students graduated from Georgia's medical schools, but only two of them chose to remain in the state to pursue a family medicine residency," the Atlanta Journal-Constitution reports. "Overall, 20 students, or 5 percent, chose to go into family medicine - half the number that it was just five years ago.

Program Provides Teachers In Papua New Guinea With HIV/AIDS Training

Primary public school teachers in Papua New Guinea's capital of Port Moresby recently completed a two-week workshop aimed at providing them with the skills to teach young people about HIV/AIDS prevention, Papua New Guinea's Post-Courier reports. The program was run by the country's Education Department and

Successful Techniques for Monitoring Medical Devices

Limdato, www.limdato.com knows that you will never see effective monitoring results unless you know the “red flag” issues in your trial. Most monitors do not focus their monitoring efforts where they are needed most. Clinical Trial Monitors need to quickly distinguish between ...
(613) 686-5745 Cerepotec Pharmalef

1994 Group Report Calls On Universities, Employers And Government To Support Programmes To Enhance Graduate Employability, UK

Universities, employers and the Government must do more to support programmes and awards that enhance graduate employability according to a report launched on Thursday by the 1994 Group of leading research-intensive universities. Professor Janice Kay, Chair of the 1994 Group's Student Experience Policy Group and Senior Deputy Vice-Chancellor, University of Exeter said: "The graduate employment market is extremely competitive.

Fees Frozen For Doctors Completing Specialty/GP Training

The GMC and PMETB have announced that the fees for trainee doctors completing specialty/GP training - and those seeking certification via the equivalence routes - will be frozen at the current levels for 2010/11. The Government announced that PMETB would be merged with the GMC following an independent inquiry into 'Modernising Medical Careers' led by Sir John Tooke.

Medical School: Beyond The Books

Textbooks and lecture notes overtaking living space, instead of Mom's chocolate cake, index cards with recipes for fighting diseases, and the smell of the anatomy lab an ever present odor medical school. Though studying remains paramount, Loyola University Chicago Stritch School of Medicine (SSOM) students are getting out from behind the books and making an impact by volunteering in their local Maywood community, across the Chicago area and around the world.

Kriger Research Group International provides clinical research services on a truly global scale.

Kriger Research Group International www.krigerclinical.com provides clinical research services for pharmaceutical and biotechnology product development from phase II through phase IV for US, Canadian, European and multinational pharmaceutical companies. KRGI is your way to high quality ...
(613) 686-5745 Cerepotec Pharmalef

Junior Doctor Training Affected By Service Reorganisation

New systems being trialled for assessing and reviewing patients may have a negative effect on junior doctor training, according to a new study of acute care at the Royal Liverpool University Hospital. The findings, published in Clinical Medicine this week, show that while NHS targets are being met, trainees' learning opportunities have suffered.

Why One Way Of Learning Is Better Than Another

A new study from the Montreal Neurological Institute and Hospital (The Neuro) of McGill University reveals that different patterns of training and learning lead to different types of memory formation.

Support For Minority Medical Students To Pursue Hematology Research

The American Society of Hematology (ASH) announces the selection of 15 participants for its 2009 Minority Medical Student Award Program (MMSAP), which encourages minority medical students to pursue an interest in hematology research. Under the program, each award recipient will receive the support of a research mentor and a career development mentor, travel stipends to attend the ASH annual meeting, and a subscription to the scientific journal Blood, the official journal of ASH.

Understanding Your Liability and Confidentiality in Clinical Trials

Clinproxy, www.clinproxy.com fully understands the issues, laws risks and best practices relating to disclosures of confidential information about clinical trials. Early information about a clinical trial is extremely valuable. The information can be indiscreetly passed on to many people ...
(613) 686-5745 Cerepotec Pharmalef

Government Study Endorses AMA Calls For Greater Investment In Medical Workforce Training, Australia

The Australian Medical Education Study report - What makes for success in medical education? - endorses calls by the AMA for greater investment in medical education and training to produce a medical workforce capable of meeting the future health needs of a growing and ageing population...

States Work To Avoid Nurse Shortage By Investing In Education Programs, Improving Hospital Working Conditions

More than two-thirds of states have allocated funding to nursing education programs over the past five years in an effort to address a looming nationwide nursing shortage, Stateline.org reports. According to a 2004 report by the Health Resources and Services Administration, the U.S. is expected to have a shortage of one million nurses by 2020.

70 Doctoral Fellowships Funded By NSF To Move Stem Cell Discoveries From Bench To Bedside

Rutgers University has received a $3.2 million grant from the National Science Foundation (NSF) to apply engineering, physical science and mathematical disciplines to stem cell research. In funding 70 doctoral fellowships, the program can equip experts in fields such as cell and molecular biology, computational modeling and biomaterials to move stem-cell breakthroughs from the biology lab into practical and commercially viable therapies.

What Clinical Research Is All About

How can researchers prove to the government that a newly-discovered drug or device is safe and effective? This is where the clinical trial comes in. The clinical trial is a research study designed to determine if a new pharmaceutical or medical device is sufficiently safe and effective for ...
(613) 686-5745 Cerepotec Pharmalef

In Wake Of Hurricane Ike, APS Sets Aside $50,000 To Help Students, Post-Docs,

The American Physiological Society has established the Hurricane Ike Relief Fund to provide unrestricted grants of up to $2,000 to support physiology graduate students and postdoctoral fellows who suffered losses as a result of Hurricane Ike. The powerful storm hit the Texas coast on Sept. 13 and also affected other areas of the country. The grants are targeted to students and fellows who are either APS members or working in the laboratories of APS members.

American Society Of Hematology Awards Grants To Encourage Novel Medical Training Programs

The American Society of Hematology (ASH) announces that Ellis J. Neufeld, MD, PhD, of Harvard Medical School, Thomas Shea, MD, of University of North Carolina at Chapel Hill, and Alvin Schmaier, MD, of Case Western Reserve University in Cleveland, will each receive ASH's Alternative Training Pathway Grant this July.

HealthPartners And American Hospital Association Partner For National Launch Of Joining Forces

HealthPartners Institute for Medical Education and the American Hospital Association (AHA) have partnered with more than a dozen national organizations to launch an initiative designed to generate awareness among medical professionals and others within communities about the challenges -- medical, social and emotional -- that veterans and their families face as they return home from military service.

Kriger Courses Are Indispensable To Break Into The Biopharmaceutical And Clinical Research Industry.

From what many of our students have said, Kriger www.kriger.com and their professional development courses are not only inspiring but also indispensable when trying to start a career in the biopharmaceutical and clinical research industry. These courses provide the necessary detailed ...
(613) 686-5745 Cerepotec Pharmalef

Final Reminder! Preregistration Trainee Pharmacist Training Programme - Last Few Places Remaining

The NPA is encouraging all prereg tutors to book their prereg pharmacists on to the NPA programme as soon as possible to avoid disappointment due to the limited number of places remaining. The programme commences in October 2009 and candidates have a choice of 3 study venues to choose from: Birmingham, St Albans and Wakefield. Sabina Khanom NPA Assistant Head of Education and Training said: "This programme is open to all preregistration trainee pharmacists working for NPA members.

American Medical Student Association Commends PhRMA's Gift Restrictions; Calls For Further Government Regulation

The American Medical Student Association (AMSA), the nation's largest independent medical student organization, supports changes made in the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals. The new code, to which pharmaceutical companies may voluntarily subscribe, acknowledges that gifts do not belong in the health care system. "However, the updates are clearly inadequate," says Dr.

Tree Of Life Award Received By Jefferson Doctor

Edith P. Mitchell, M.D., clinical professor, Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University and associate director of Diversity Programs for the Kimmel Cancer Center at Jefferson, was recently honored with a 'Tree of Life' award from The Wellness of You, a local nonprofit health education and resource organization. The Tree of Life award recognizes health professionals who are committed to making a difference in community health.

ClinQua Inc. is one of CRO's focusing the Investigator on aspects critical for validating the drugs' therapeutic benefits.

ClinQua Inc. www.clinqua.com is one of CRO's (Contract Research Organizations), who specialize in evaluating the demands of the trial and eliminating redundant protocols and focusing the Investigator on aspects critical for validating the drugs' therapeutic benefits. Common sense would ...
(613) 686-5745 Cerepotec Pharmalef

African Institutions Lead International Consortia In $49 Million Initiative

More than fifty institutions from eighteen African countries - from Senegal to Sudan to South Africa - are to participate in international consortia under a £30 million initiative from the Wellcome Trust to strengthen research capacity on the continent. Africa is affected by some of the world's deadliest diseases, including HIV, malaria and tuberculosis.

U.S. Medical Students Call On President-Elect Obama To Deliver Accessible Health Care System

The American Medical Student Association (AMSA), the nation's oldest and largest, independent association for physicians-in-training, congratulates President-elect Barack Obama and urges him to move the country toward a health care system that delivers accessible, affordable, high-quality health care to all Americans. "The country is in a state of crisis," says Dr. Brian Hurley, AMSA's national president.

Faculty Of Translational Medicine Boosts Support For Biomedical Researchers

A new Faculty of Translational Medicine has been launched to increase support for, and enhance collaboration among researchers as they search for new treatments and diagnostic tests for a range of diseases and conditions. The Faculty is based in the National Institute for Health Research Comprehensive Biomedical Research Center at Guy's and St Thomas' hospitals and King's College London.

Anestvice Inc. Phase II Clinical Trials for PC-LM Device have been successfully completed.

The research was conducted on 24 patients ranging in age from 13 to 74 years (the average age was 46.6 ±5.4), who underwent surgery in the urology clinic of the Rostov State Medical University. It was sponsored by Anestvice Inc. www.anestvice.com Baltimore based research and development ...
(613) 686-5745 Cerepotec Pharmalef

Virology Text Focuses On Families

A new virology textbook published by ASM Press educates the reader by focusing on the families. Based on the author's experiences teaching virology for more than 35 years, Virology: Molecular Biology and Pathogenesis enables readers to develop a deep understanding of fundamental virology by emphasizing principles and discussing viruses in the context of virus families...

Australian Medical Students Association: Medical Training Solutions For National Doctor Shortage

The Australian Medical Students' Association (AMSA) has reiterated calls for State and Federal Governments to urgently address the shortage of clinical training places available to medical students and junior doctors. The number of medical students graduating annually in Australia is expected to increase almost three fold in 10 years, from 1200 in 2002 to 3300 in 2012.

Initiatives, Events Offer Training To HIV/AIDS Workers, Educate Families On Children's Exposure To Toxins, Expand Services To American Indians

The following highlights initiatives and events that seek to reduce racial and ethnic health disparities.Denver: The National Native American AIDS Prevention Center is working with agencies to train public health workers in hopes of reducing the spread of HIV/AIDS among American Indians,

Understanding the Importance of ICH GCP is Vital to the Continued Safety of Clinical Patients.

Several Kriger www.krigerinternational.com course sessions are dedicated to understanding concepts and principles that have helped mold the industry into what it is today. This gives each student the opportunity to understand how the industry is progressing, so that when they take their place ...
(613) 686-5745 Cerepotec Pharmalef

Health Care Professionals Failing To Tell Patients They Are Not Fit To Drive

Many healthcare professionals are failing to advise people with medical conditions that could affect their ability to drive whether they should get behind the wheel, according to research from the University of Warwick...

Obama Administration Announces More Than $327 Million In Recovery Act Funding For Science Research

U.S Department of Energy Secretary Steven Chu has announced that more than $327 million in new funding from the American Recovery and Reinvestment Act will go toward scientific research, instrumentation, and laboratory infrastructure projects. Ten of DOE's national laboratories in six states will be receiving funds, along with researchers at institutions of higher learning across the nation. "These new initiatives will help to create new jobs while allowing the U.S.


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .<br />In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture. <br /><br />One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound. <br />The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material. <br /><br />Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV. <br /><br />This step can be repeated in the future in order to produce more of compound III. <br />Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.<br /><br />Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment. <br /><br />At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.<br />Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.<br /><br />In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.<br />US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex. <br /><br />This company is also developing a family of other promising novel chemical compounds. <br /><br />Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans. <br />Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.<br /><br />Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.<br />Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.<br /><br />Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.<br /><br />Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer. <br /><br />Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union. <br />Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.<br /><br />In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.<br />Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market. <br /><br />Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations. <br />Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.<br /><br />They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities. <br /><br />They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.<br />CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008<br /><br />A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838<br /><br />1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.<br /><br />2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.<br /><br />3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.<br /><br />4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.<br /><br />5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.<br /><br />6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.<br /><br />7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.<br /><br />9. The method according to claim 8, wherein said head trauma injury is closed head injury.<br /><br />10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.<br /><br />11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.<br /><br />12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.<br /><br />13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.<br /><br />14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.<br /><br />15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.<br /><br />16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.<br /><br />17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.<br /><br />18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.<br /><br />19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.<br /><br />21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.


Viev all previous articles...

Some Article Feeds provided by MedicalNewsToday.com

More Articles of interest...

Burn Treatment Employing Nanoparticles Curbs Infection, Reduces Inflammation

Treating second-degree burns with a nanoemulsion lotion sharply curbs bacterial growth and reduces inflammation that otherwise can jeopardize recovery, University of Michigan scientists have shown in initial laboratory studies. U-M burn surgeon Mark R. Hemmila, M.D., reports today at the Interscience Conference for Antimicrobial Agents and Chemotherapy on results achieved with a nanoemulsion developed at U-M and licensed by U-M to Ann Arbor-based NanoBio Corporation.

ACZ885 Phase III Data Show Rapid, Sustained Clinical Remission In Children And Adults Suffering From A Group Of Rare Autoinflammatory Diseases

New Phase III data demonstrate that ACZ885 (canakinumab), a biological drug in development, achieved rapid and long-lasting clinical remission after just one dose in children and adults with a group of rare but potentially life-threatening autoinflammatory diseases called Cryopyrin-Associated Periodic Syndromes (CAPS)1. Due to the long duration of response, patients only needed further treatment every two months1.

Effective MRI Correlate For Identifying Incidental Breast Lesions Not Seen On Mammography And First Look Ultrasound

A second look ultrasound of the breast, used in conjunction with MRI, allows radiologists to identify lesions not detected on conventional mammography and first look ultrasound; in some cases it allows radiologists to determine whether or not a lesion is malignant or benign, according to a study performed at the University of Rome La Sapienza in Rome, Italy. The study included 182 patients who had mammography, ultrasound and MRI.

Clinical Trials Do Not Need To Be Expensive!

Many CRO Directors will argue that the foreseeable burden of clinical investigation is cost and the weight of that burden falls onto clients. The clinical climate has seen extraordinary escalation in federal regulations to make sure that the integrity of the products that are ...
(613) 686-5745 Cerepotec Pharmalef

Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon Added To Donepezil In Patients With Alzheimer's Disease

Pfizer (NYSE: PFE) and Medivation, Inc. (Nasdaq: MDVN) announced the initiation of a 12-month, Phase 3 clinical trial of the investigational drug Dimebon. The study, known as CONCERT, is designed to evaluate the safety and efficacy of Dimebon when added to ongoing treatment with donepezil HCI tablets, the leading Alzheimer's disease (AD) medication worldwide, in patients with mild-to-moderate AD.

Sucampo Initiates Pivotal Phase 3 Efficacy Trial Of Lubiprostone For Chronic Idiopathic Constipation In Japan

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), an international biopharmaceutical company, announced that its subsidiary, Sucampo Pharma, Ltd., has initiated enrollment and completed the randomization of the first patient into the pivotal phase 3 efficacy trial of lubiprostone for chronic idiopathic constipation (CIC) in Japan. Under the terms of a license, commercialization and supply agreement Sucampo signed in February 2009 with Abbott Japan Co., Ltd.

Deep Brain Stimulation Found To Be Effective In Children With Treatment-Resistant Generalized Primary Dystonia

Dystonia is a very complex, highly variable neurological movement disorder characterized by involuntary muscle contractions. As many as 250,000 people in the United States have dystonia, making it the third most common movement disorder behind essential tremor and Parkinson's disease. The prevalence of generalized primary dystonia is estimated at 34 in 100,000 people worldwide, but cited statistics vary. This figure is most likely an underestimate, since many cases go undiagnosed for years.

Cereprotex displayed a significant anti-edema effect in a model of closed head injury.

Cereprotex displayed a significant anti-edema effect in a model of closed head injury. It significant decreases in the degree of edema developed after injury was found following treatment postponed one hour after traumatic injury. About 35% less water accumulated in the traumatized hemisphere ...
(613) 686-5745 Cerepotec Pharmalef

Schering Plough Highlights Hepatitis C Clinical Data Presentations At The European Association For The Study Of The Liver (EASL) Annual Meeting

Schering-Plough Corporation (NYSE: SGP) reported that final results of three large PEGINTRON(TM) (peginterferon alfa-2b) clinical studies address longstanding questions in the hepatitis C research community and provide important insights. The results of the studies, involving a total of more than 2,700 patients, were presented at the 44th European Association for the Study of the Liver (EASL) 2009 Annual Meeting.

CEL-SCI To Commence First Clinical Study With Hospitalized H1N1 Infected Patients

CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that the U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

It Pays To Quit Smoking Before Surgery

People who start nicotine replacement therapy at least four weeks before surgery can halve their risk of poor wound healing. This is what the German Institute for Quality and Efficiency in Health Care (IQWiG) concludes in information published on http://informedhealthonline.org/.

Clinproxy: In general the overall expense of clinical trials depends on a multitude of factors

In an ever growing global market of supply and demand, it remains unimaginable to engage in practices that are ambitiously expensive when there are endless opportunities to utilize more appropriately priced methods which would in turn yield the same results. The overall cost of clinical trials ...
(613) 686-5745 Cerepotec Pharmalef

Array BioPharma Initiates Clinical Trial In Type 2 Diabetic Patients

Array BioPharma Inc. (Nasdaq: ARRY) announced that it has dosed its first Type 2 diabetic patient in a Phase 1 clinical trial with its novel small molecule glucokinase activator (GKA), ARRY-403. In preclinical studies, ARRY-403 demonstrated effective control of both fasting and non-fasting blood glucose concentrations. The GKA activity of ARRY-403 was shown to be highly dependent on blood glucose concentrations.

Nektar Completes Enrollment Ahead Of Schedule In Phase 2 Clinical Trial Evaluating NKTR-102 In Patients With Platinum-Resistant Ovarian Cancer

Nektar Therapeutics (Nasdaq: NKTR) announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

Experimental Drug RGN-259 Promotes Healing In Patients With Non-Healing Corneal Ulcers - Four Patients Treated Under "Compassionate Use" IND

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that its ophthalmic drug candidate, RGN-259, was used to treat four neurotrophic keratitis patients with non-healing eye ulcers caused primarily by the herpes zoster virus under a "Compassionate Use" IND (Investigational New Drug application). RGN-259 is a sterile eye drop formulation of Tβ4 being developed by RegeneRx for use in treating ophthalmic wounds and related disorders. Dr.

Limdato’s Grasp On Streamlining Clinical Trials

Limdato, www.limdato.com understands that executing a successful clinical trial requires a seamless coordination and communication with all individuals involved on levels on the trial. On average clinical trials in Phases 1,2,3 go beyond deadlines by 30%. These delays cost the ...
(613) 686-5745 Cerepotec Pharmalef


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .<br />In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture. <br /><br />One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound. <br />The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material. <br /><br />Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV. <br /><br />This step can be repeated in the future in order to produce more of compound III. <br />Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.<br /><br />Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment. <br /><br />At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.<br />Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.<br /><br />In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.<br />US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex. <br /><br />This company is also developing a family of other promising novel chemical compounds. <br /><br />Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans. <br />Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.<br /><br />Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.<br />Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.<br /><br />Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.<br /><br />Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer. <br /><br />Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union. <br />Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.<br /><br />In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.<br />Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market. <br /><br />Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations. <br />Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.<br /><br />They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities. <br /><br />They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.<br />CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008<br /><br />A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838<br /><br />1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.<br /><br />2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.<br /><br />3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.<br /><br />4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.<br /><br />5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.<br /><br />6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.<br /><br />7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.<br /><br />9. The method according to claim 8, wherein said head trauma injury is closed head injury.<br /><br />10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.<br /><br />11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.<br /><br />12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.<br /><br />13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.<br /><br />14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.<br /><br />15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.<br /><br />16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.<br /><br />17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.<br /><br />18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.<br /><br />19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.<br /><br />21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.
HOME . ARTICLESMORE FEATURES .  CONTACT

613-686-5745 Clinical training is not a Scam, you should take training courses that are not a scam. Not a clinical trial scam for training in the clinical trail industry. Clinical Research Associate Courses maybe not a scam but not really a scam you learn alot about Clinic trials. Don't tell me its a scam as I think it does not work. Opinions of Clinical Training seem to say these courses are a scam. This is not truly a scam, scams are not good and clinical trails is not one of them. Take Clinical courses and you won't be scammed. Is Clinical Research Associates Training a scam? 613-686-5745

And a pair of them on 800notes.com. pharmaceutical company you hope to one day work for. Similar to comments bearing the same signature and left elsewhere, it includes talk of defamation, and “offensive or harassing content” removing this blog trinity includes a recruiting agency, a pharma company, and a school

INSTITUTIONS THAT OFFERS A PRACTICAL ORIENTED COURSE IN CLINICAL RESEARCH.ClinfoSource online GCP training courses WARN OF ONE INSTITUTE. STAY AWAY. they will help you find a job in India. certificates courses, numerous spelling and grammar mistakes. Looking for clinical research staff nation-wide to prepare and initiate clinical trials. report a fraud. report this scam. moving forward in their clinical trial as it was approved.Espoir and PharmAlef are a complete and utter fraud

qualified for any clinical trials-related positions, but we highly recommend you get a clinical trials certificate. QA experience: GMP, GLP and GCP certificate through the training and certification  programs accredited by the International Biopharmaceutical Association. Certificate form Kriger and Bachelor's degree in science and clinical research experience preferred. I am still interested in pursuing a career in clinical research. 613-686-5745

http://www.clinicaltoday.com/ . http://pharmaindustrytoday.com/ . http://www.medicaltrainingtoday.com/ . http://medicalnewspress.com . http://medicaldevicesnews.com . http://MedConferencestoday.com . http://regulatoryaffairstoday.com